About this trial
In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This study is a phase IV clinical study designed and carried out by the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), which is a randomized, open and routine treatment group with parallel control.
Eligibility criteria
Qualifiers
Graves hyperthyroidism (responsible for doctors' clinical diagnosis)
Age 18-65, for both men and women
Thyroid receptor antibody (TRAb) was positive
Take part in this research voluntarily and sign the informed consent form
Disqualifiers
Those who have used glucocorticoid or other immunosuppressants for a long time within 3 months before being selected
Those who have participated in any other drug trials within 3 months before being selected
Subjects who are participating in clinical research of other drugs
Patients with a history of malignant tumors
Trial design
Treatments tested in this trial
- Methimazole
Treatment groups
Locations
1Sponsors and collaborators
The First Affiliated Hospital with Nanjing Medical University
Lead sponsor